Acrivon Therapeutics, Valuation
| ACRV Stock | 6.55 0.11 1.71% |
At this time, the firm appears to be overvalued. Acrivon Therapeutics, shows a prevailing Real Value of 6.12 per share. The current price of the firm is 6.55. Our model approximates the value of Acrivon Therapeutics, from analyzing the firm fundamentals such as Return On Equity of -0.38, shares owned by insiders of 22.38 %, and Current Valuation of 17.08 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Acrivon Therapeutics,'s valuation include:
Price Book 1.0184 | Enterprise Value 17.1 M | Enterprise Value Ebitda (0.43) |
Overvalued
Today
Please note that Acrivon Therapeutics,'s price fluctuation is slightly risky at this time. Calculation of the real value of Acrivon Therapeutics, is based on 3 months time horizon. Increasing Acrivon Therapeutics,'s time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Acrivon stock is determined by what a typical buyer is willing to pay for full or partial control of Acrivon Therapeutics, Common. Since Acrivon Therapeutics, is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Acrivon Stock. However, Acrivon Therapeutics,'s intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 6.55 | Real 6.12 | Target 23.13 | Hype 6.44 | Naive 5.62 |
The intrinsic value of Acrivon Therapeutics,'s stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Acrivon Therapeutics,'s stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Acrivon Therapeutics, Common helps investors to forecast how Acrivon stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Acrivon Therapeutics, more accurately as focusing exclusively on Acrivon Therapeutics,'s fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Acrivon Therapeutics,'s intrinsic value based on its ongoing forecasts of Acrivon Therapeutics,'s financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Acrivon Therapeutics,'s closest peers.
Acrivon Therapeutics, Cash |
|
Acrivon Valuation Trend
Analysing the historical paterns of Acrivon Therapeutics,'s enterprise value and its market capitalization is a good way to estimate and gauge the value of Acrivon Therapeutics, Common over time and is usually enough for investors to make rational market timing decisions.
Acrivon Therapeutics, Total Value Analysis
Acrivon Therapeutics, Common is presently projected to have valuation of 17.08 M with market capitalization of 200.52 M, debt of 4.64 M, and cash on hands of . Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Acrivon Therapeutics, fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
17.08 M | 200.52 M | 4.64 M |
Acrivon Therapeutics, Asset Utilization
One of the ways to look at asset utilization of Acrivon is to check how much profit was generated for every dollar of assets it reports. Acrivon Therapeutics, Common shows a negative utilization of assets of -0.24 percent, losing 0.002441 for each of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each of assets it shows. Put another way, asset utilization of Acrivon Therapeutics, Common shows how discouraging it operates for each spent on its assets.Acrivon Therapeutics, Ownership Allocation
Acrivon Therapeutics, holds a total of 31.14 Million outstanding shares. The majority of Acrivon Therapeutics, Common outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Acrivon Therapeutics, to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Acrivon Therapeutics,. Please pay attention to any change in the institutional holdings of Acrivon Therapeutics, Common as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Acrivon Therapeutics, Profitability Analysis
Net Loss for the year was (60.39 M) with profit before overhead, payroll, taxes, and interest of 0.About Acrivon Therapeutics, Valuation
Our relative valuation model uses a comparative analysis of Acrivon Therapeutics,. We calculate exposure to Acrivon Therapeutics,'s market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Acrivon Therapeutics,'s related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -536 K | -562.8 K |
Acrivon Therapeutics, Growth Indicators
Investing in growth stocks can be very risky. If the company such as Acrivon Therapeutics, does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 22.1 M |
Acrivon Therapeutics, Current Valuation Indicators
Acrivon Therapeutics,'s valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Acrivon Therapeutics,'s valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Acrivon Therapeutics,, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Acrivon Therapeutics,'s valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Acrivon Therapeutics,'s worth.Additional Tools for Acrivon Stock Analysis
When running Acrivon Therapeutics,'s price analysis, check to measure Acrivon Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acrivon Therapeutics, is operating at the current time. Most of Acrivon Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Acrivon Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acrivon Therapeutics,'s price. Additionally, you may evaluate how the addition of Acrivon Therapeutics, to your portfolios can decrease your overall portfolio volatility.